APA (7th ed.) Citation

Lu, C., Wei, X., Zhang, Y., Chen, Z., Xu, C., Zheng, M., . . . Zhou, Q. (2023). Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes. Journal of Cancer Research & Clinical Oncology, 149(7), 2987. https://doi.org/10.1007/s00432-022-04188-7

Chicago Style (17th ed.) Citation

Lu, Chang, Xue-Wu Wei, Yi-Chen Zhang, Zhi-Hong Chen, Chong-Rui Xu, Ming-Ying Zheng, Jin-Ji Yang, Xu-Chao Zhang, and Qing Zhou. "Selective RET Inhibitors Shift the Treatment Pattern of RET Fusion-positive NSCLC and Improve Survival Outcomes." Journal of Cancer Research & Clinical Oncology 149, no. 7 (2023): 2987. https://doi.org/10.1007/s00432-022-04188-7.

MLA (9th ed.) Citation

Lu, Chang, et al. "Selective RET Inhibitors Shift the Treatment Pattern of RET Fusion-positive NSCLC and Improve Survival Outcomes." Journal of Cancer Research & Clinical Oncology, vol. 149, no. 7, 2023, p. 2987, https://doi.org/10.1007/s00432-022-04188-7.